Stay updated on Pembrolizumab in Recurrent PCNSL Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Recurrent PCNSL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Recurrent PCNSL Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    A new site revision label v3.6.6 was added, replacing the previous v3.6.5. This indicates a small deployment to the ClinicalTrials.gov interface.
    Difference
    0.1%
    Check dated 2026-08-30T11:29:07.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    No Change Detected
  5. Check
    29 days ago
    Change Detected
    Summary
    The page's revision tag changed from v3.6.4 to v3.6.5, indicating a minor update to the page template or content-management system. This update does not modify study details or visible content.
    Difference
    0.1%
    Check dated 2026-08-09T00:41:25.000Z thumbnail image
  6. Check
    44 days ago
    Change Detected
    Summary
    The page’s revision identifier was updated from v3.6.3 to v3.6.4. This indicates the study page has been refreshed to a newer revision.
    Difference
    0.1%
    Check dated 2026-07-25T17:07:25.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    The page now displays an updated revision tag from v3.6.2 to v3.6.3, indicating a recent backend/frontend update to the page.
    Difference
    0.1%
    Check dated 2026-07-04T06:00:22.000Z thumbnail image
  8. Check
    72 days ago
    Change Detected
    Summary
    Revision: v3.6.2 replaces v3.6.0 on the page, indicating an updated build of the site's software or content management. The update reflects a software version change rather than substantive changes to the study details.
    Difference
    0.1%
    Check dated 2026-06-27T03:55:54.000Z thumbnail image
  9. Check
    86 days ago
    Change Detected
    Summary
    New entries identify the investigator and sponsoring institution (Prof. Dr. Matthias Preusser; Medical University of Vienna) and add user-focused navigation items (How to Read a Study Record, Common Questions, How to Join a Study). Additionally, the page labels are updated (Intervention/Treatment) and a new revision tag (Revision: v3.6.0) is introduced.
    Difference
    2%
    Check dated 2026-06-13T00:31:24.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Recurrent PCNSL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent PCNSL Clinical Trial page.